Next |
home / stock / blrx / blrx message board
Subject | By | Source | When |
---|---|---|---|
BioLineRx to Report First Quarter 2023 Results on | midastouch017 | investorshub | 05/17/2023 12:03:40 PM |
Philip Serlin: I would like to take a | midastouch017 | investorshub | 05/11/2023 5:17:14 PM |
1.6792+0.1692 (+11.2053%) | midastouch017 | investorshub | 05/11/2023 3:10:39 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 05/11/2023 2:03:17 PM |
Three out of four: Protlix also received marketing | midastouch017 | investorshub | 05/11/2023 12:48:56 PM |
Yes! Having some fun today. Maybe it's better | RickSanchez316 | investorshub | 05/10/2023 5:45:51 PM |
$BLRX doing quite well, don't you agree? | midastouch017 | investorshub | 05/10/2023 2:52:01 PM |
BioLine RX ($BLRX) | midastouch017 | investorshub | 05/10/2023 3:28:12 AM |
$BLRX - our next skyhigh hopes? | midastouch017 | investorshub | 05/05/2023 1:36:03 PM |
$BLRX MomentumIts now | midastouch017 | investorshub | 04/30/2023 8:08:40 PM |
great news | midastouch017 | investorshub | 04/29/2023 6:21:25 PM |
$BLRX are we finally gonna see some action | midastouch017 | investorshub | 04/29/2023 6:14:33 PM |
$BLRX news all the way baby | jcon777 | investorshub | 04/26/2023 7:57:11 AM |
BioLineRx regains Nasdaq compliance | midastouch017 | investorshub | 04/25/2023 12:11:46 PM |
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | midastouch017 | investorshub | 04/25/2023 12:00:17 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 04/25/2023 1:50:24 AM |
is it bear time? Or do we go bull? | midastouch017 | investorshub | 04/24/2023 11:19:31 PM |
Found an interesting article | jcon777 | investorshub | 04/24/2023 7:21:42 PM |
$BLRX When is this gonna take off? | midastouch017 | investorshub | 04/23/2023 2:02:29 AM |
The gaining last trade up | midastouch017 | investorshub | 04/22/2023 8:55:54 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...